SCHEMBL24004064

SCHEMBL24004064

N#Cc1ccc2nccc(Nc3ccc(-c4nc5nc(Nc6ccncc6)ccc5[nH]4)cc3)c2c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK2 P49137 2/20 0.49
▸ PKN1 Q16512 1/20 0.46
▸ PKN2 Q16513 1/20 0.46
▸ KDR P35968 11/20 0.44
▸ GAK O14976 1/20 0.44
▸ RIPK2 O43353 1/20 0.44
▸ COQ8A Q8NI60 1/20 0.44
▸ NLK Q9UBE8 1/20 0.44
▸ LRRK2 Q5S007 2/20 0.41
▸ RAF1 P04049 1/20 0.41
▸ BRAF P15056 1/20 0.41
▸ PRMT5 O14744 1/20 0.40
▸ CSNK1A1 P48729 1/20 0.39
▸ CSNK1D P48730 1/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ CSNK1G2 P78368 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30180523 1.00 MAPKAPK2 (0.49) MAPKAPK2PKN1PKN2KDRGAK
SCHEMBL23999401 0.91 MAPKAPK2 (0.51) MAPKAPK2KDRGAKRIPK2COQ8A
SCHEMBL23999396 0.88 MAPKAPK2 (0.52) MAPKAPK2PKN1PKN2KDRGAK
SCHEMBL23999513 0.86 MAPKAPK2 (0.52) MAPKAPK2PKN1PKN2KDRGAK
SCHEMBL23999449 0.86 MAPKAPK2 (0.52) MAPKAPK2PKN1PKN2KDRGAK
SCHEMBL23999408 0.86 MAPKAPK2 (0.49) MAPKAPK2PKN1PKN2KDRGAK
SCHEMBL23999350 0.85 KDR (0.59) MAPKAPK2PKN1PKN2KDRGAK
SCHEMBL23999436 0.85 KDR (0.59) MAPKAPK2PKN1PKN2KDRGAK
SCHEMBL23999403 0.84 LRRK2 (0.43) MAPKAPK2PKN1PKN2KDRGAK
SCHEMBL23999400 0.83 MAPKAPK2 (0.43) MAPKAPK2KDRGAKRIPK2COQ8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 — — US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 — — US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 — — WO disclosed
CN-115996939-A AKT3 modulators 乔治穆内有限责任公司 2023-04-21 — — CN disclosed
CN-115867562-A AKT3 modulators 乔治穆内有限责任公司 2023-03-28 — — CN disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR MAPKAPK2 151/4885PKN1 856/4885PKN2 582/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR MAPKAPK2 138/4885PKN1 781/4885PKN2 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback